In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sudan renews medtech prospects:

This article was originally published in Clinica

Executive Summary

International healthcare efforts in the Darfur region of Sudan are set to resume, after the government signed a series of security and humanitarian access agreements yesterday. The move is in response to widespread condemnation of the severe social instability in the region. The situation has essentially obviated the calls made in July to meet shortfalls in medical supplies and diagnostic services and hospital infrastructures (see Clinica No 1117, p 13). International efforts were expected to resume last week, after the government signed a series of security and humanitarian access agreements, in response to widespread condemnation of the severe social instability in the region. The UN Security Council met on November 18, in Nairobi, Kenya, to discuss the situation and consider sanctions.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel